Margarita Eversdijk

Margarita Eversdijk

Auto-generated profile, based on publicly available information

Margarita Eversdijk


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Bulletin of the Academy of Sciences of Moldova. Medical Sciences
Verified
Journal Article
Closed access
MEMargarita Eversdijk
Margarita Eversdijk
MSMarina Sangheli
Marina Sangheli
VLVitalie Lisnic
Vitalie Lisnic
VSVictoria Simon
Victoria Simon
ABAnna Belenciuc
Anna Belenciuc
Ocrelizumab, a humanized monoclonal antibody that targets CD20-positive B cells, has significantly advanced the treatment of multiple sclerosis (MS). Approved for both relapsing-remitting MS and primary progressive MS, it represents a novel approach in MS therapy. Since the end of 2023, Republic of Moldova has incorporated ocrelizumab into its national treatment guidelines, providing access to this innovative therapy for its population. This review provides a detailed analysis of ocrelizumab’s mechanism of action, clinical efficacy, safety profile, and long-term impact based on data from clinical trials and real-world studies. Additionally, the review explores ocrelizumab’s comparison with other disease-modifying therapies, its role in patient quality of life, and the future direction of MS treatment.